Increased non-classical monocytes are correlated with favorable outcome in NSCLC patients receiving anti-PD-1 antibody monotherapy, while the opposite was observed for PD-L1-expressing classical monocytes (32). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.